Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antenatal ferric carboxymaltose dose comparison in pregnant women with iron deficiency
ACTRN12615000950561Phase 4Completed
- Sponsor
- Lyell McEwin Hospital
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of ferric carboxymaltose in iron deficiency anemia (IDA) (2 arms), sponsored by Lyell McEwin Hospital. Primary endpoint: Need for additional intravenous iron. Started Apr 2015; status: completed.
02
Drugs
ferric carboxymaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on ACTRN12615000950561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615000950561.